Agomelatine
Agomelatine (trade names Valdoxan, Melitor, Thymanax) is an antidepressant developed by the pharmaceutical company Servier. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, which enhances the activity of frontocortical dopaminergic and adrenergic pathways.  It is the first melatonergic antidepressant. Because of its unique profile, agomelatine has not been associated with weight gain, sexual side effects, or withdrawal syndrome; this is in contrast to most SSRIs and many antidepressants.